These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26678555)

  • 21. A bacteriophage journey at the European Medicines Agency.
    Debarbieux L; Pirnay JP; Verbeken G; De Vos D; Merabishvili M; Huys I; Patey O; Schoonjans D; Vaneechoutte M; Zizi M; Rohde C
    FEMS Microbiol Lett; 2016 Jan; 363(2):fnv225. PubMed ID: 26656541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches.
    Chanishvili N
    Adv Virus Res; 2012; 83():3-40. PubMed ID: 22748807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
    Dwenger A; Strassburger J; Schwerdtfeger W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Georgia: an unlikely stronghold for bacteriophage therapy.
    Parfitt T
    Lancet; 2005 Jun 25-Jul 1; 365(9478):2166-7. PubMed ID: 15986542
    [No Abstract]   [Full Text] [Related]  

  • 25. Phage approved in food, why not as a therapeutic?
    Sarhan WA; Azzazy HM
    Expert Rev Anti Infect Ther; 2015 Jan; 13(1):91-101. PubMed ID: 25488141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is needed for phage therapy to become a reality in Western medicine?
    Brüssow H
    Virology; 2012 Dec; 434(2):138-42. PubMed ID: 23059181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programming Bacteriophages by Swapping Their Specificity Determinants.
    Goren MG; Yosef I; Qimron U
    Trends Microbiol; 2015 Dec; 23(12):744-746. PubMed ID: 26526502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidelines for Bacteriophage Product Certification.
    Fauconnier A
    Methods Mol Biol; 2018; 1693():253-268. PubMed ID: 29119445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis.
    Golkar Z; Bagasra O; Pace DG
    J Infect Dev Ctries; 2014 Feb; 8(2):129-36. PubMed ID: 24518621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review: phage therapy: a modern tool to control bacterial infections.
    Qadir MI
    Pak J Pharm Sci; 2015 Jan; 28(1):265-70. PubMed ID: 25553704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key issues in phage therapy: a report of a dedicated workshop at the Viruses of Microbes II meeting.
    Huys I; Vaneechoutte M; Verbeken G; Debarbieux L
    Res Microbiol; 2013 Sep; 164(7):806-10. PubMed ID: 23583722
    [No Abstract]   [Full Text] [Related]  

  • 32. [Bacteriophages as antibacterial agents].
    Shasha SM; Sharon N; Inbar M
    Harefuah; 2004 Feb; 143(2):121-5, 166. PubMed ID: 15143702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteriophage Production in Compliance with Regulatory Requirements.
    Pirnay JP; Merabishvili M; De Vos D; Verbeken G
    Methods Mol Biol; 2024; 2734():89-115. PubMed ID: 38066364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respirable bacteriophages for the treatment of bacterial lung infections.
    Hoe S; Semler DD; Goudie AD; Lynch KH; Matinkhoo S; Finlay WH; Dennis JJ; Vehring R
    J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):317-35. PubMed ID: 23597003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriophages: an appraisal of their role in the treatment of bacterial infections.
    Hanlon GW
    Int J Antimicrob Agents; 2007 Aug; 30(2):118-28. PubMed ID: 17566713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bacteriophage therapy and colleague Martin Arrowsmith].
    Nevasaari K
    Duodecim; 2003; 119(14):1367. PubMed ID: 12916189
    [No Abstract]   [Full Text] [Related]  

  • 38. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
    Mahalatchimy A; De Grove-Valdeyron N
    J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.